Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and impact of human umbilical cord MSC-derived extracellular vesicles on human embryos
jRCT1040250208Not yet recruiting
- Sponsor
- EXORPHIA
- Start
- Mar 2026
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of human umbilical cord mesenchymal stem cell-derived extracellular vesicles in infertility, sponsored by EXORPHIA. Primary endpoint: Apoptosis in blastocysts. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cell-derived extracellular vesicles
03
Conditions
infertility
Beyond the preview
Go deeper on jRCT1040250208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040250208.